13 employees
WindMIL Therapeutics translates novel insights in bone marrow immunology into life-saving cell therapies for cancer patients.
2016
$33M
from 5 investors over 5 rounds
WindMIL Therapeutics raised $33M on June 18, 2018
Investors: Medivate Partners, FoxKiser, Qiming Venture Partners, Domain Associates and Camden Partners